Announcements
- Sandoz reports first quarter 2024 sales
- Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
- Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
- Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
- Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
- Sandoz reports fourth quarter 2023 sales and full-year 2023 results
- Sandoz receives FDA approval for first and only denosumab biosimilars
- Sandoz announces nominations to the Board of Directors and leadership change
- Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
- Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
More ▼
Key statistics
As of last trade Sandoz Group AG (SDZNY:QXI) traded at 35.07, -2.93% below its 52-week high of 36.13, set on May 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 34.86 |
---|---|
High | 35.11 |
Low | 34.82 |
Bid | -- |
Offer | -- |
Previous close | 35.20 |
Average volume | 70.65k |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 21 2024 16:36 BST.
More ▼